Isopuramin (Glycine, L-Lysine Hydrochloride, L-Tryptophan, L-Arginine, L-Histidine, L-Isoleucine, L-Leucine, L-M)

Glycine, together with other essential amino acids in Isopuramin, serves as a building block for protein synthesis and participates in metabolic pathways such as gluconeogenesis and neurotransmitter production. By delivering these amino acids directly into the bloodstream, the formulation helps maintain nitrogen balance and supports tissue repair during catabolic stress.

The dose of Isopuramin is individualized and determined by the prescribing clinician based on the patient’s weight, clinical condition, renal and hepatic function, and overall nutritional requirements. Healthcare professionals calculate the appropriate infusion rate and total daily amount according to established parenteral nutrition protocols.

Safety data for Isopuramin in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful assessment.

To order Isopuramin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Isopuramin offers a balanced blend of essential and conditionally essential amino acids similar to other commercial amino‑acid solutions, but its specific composition may differ in the proportion of individual amino acids. Clinicians choose a product based on the patient’s metabolic needs, compatibility with other nutrition components, and institutional protocols.

Isopuramin must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration, and allow it to reach room temperature if required by the administration protocol.

Isopuramin is administered intravenously, typically as a continuous infusion or intermittent bolus, depending on the prescribed nutrition regimen. The infusion set‑up must follow aseptic technique, and the rate is adjusted according to the patient’s calculated amino‑acid requirements and clinical response.

Serious risks include anaphylactic reactions, severe electrolyte imbalances, metabolic acidosis, hyperammonemia, and worsening renal function. Prompt recognition of symptoms such as difficulty breathing, rapid heart rate, significant changes in blood chemistry, or reduced urine output is essential for immediate medical intervention.

Isopuramin is contraindicated in patients with known hypersensitivity to any of its amino‑acid components, those with severe hepatic failure leading to hyperammonemia, and individuals with uncontrolled electrolyte disturbances. It should also be used with caution in patients with impaired renal function or those receiving incompatible intravenous medications.